AURELIA ONLINE / マンジャロの減量
Reducing the Mounjaro Dose: When to Step Down from 7.5 mg, 5 mg, or 2.5 mg
When to reduce Mounjaro from 7.5 mg to 5 mg or from 5 mg to 2.5 mg, how dose reduction differs from extending the interval, and when urgent medical care is needed.
Key points
- Persistent nausea, vomiting, constipation, diarrhea, or difficulty maintaining food and fluid intake.
- Excessively rapid weight loss, weakness, dehydration, or declining muscle mass.
- The target weight has been reached and a lower maintenance dose is being considered.
- The previous lower dose already provided adequate appetite and glucose control.
When dose reduction may be considered
- Persistent nausea, vomiting, constipation, diarrhea, or difficulty maintaining food and fluid intake.
- Excessively rapid weight loss, weakness, dehydration, or declining muscle mass.
- The target weight has been reached and a lower maintenance dose is being considered.
- The previous lower dose already provided adequate appetite and glucose control.
Dose reduction is not the same as interval extension
- Reducing from 7.5 mg to 5 mg while continuing weekly dosing usually produces steadier exposure than taking 7.5 mg every two or three weeks.
- Planned interval extension is off-label and has less direct evidence than the standard weekly schedule.
When to seek urgent care
- Severe or persistent abdominal pain, repeated vomiting, jaundice, inability to drink, markedly reduced urination, or symptoms of severe hypoglycemia require prompt medical assessment.
- Do not simply delay the next injection and wait if a serious adverse event is suspected.
Frequently asked questions
When dose reduction may be considered?
Persistent nausea, vomiting, constipation, diarrhea, or difficulty maintaining food and fluid intake. Excessively rapid weight loss, weakness, dehydration, or declining muscle mass. The target weight has been reached and a lower maintenance dose is being considered. The previous lower dose already provided adequate appetite and glucose control.
Dose reduction is not the same as interval extension?
Reducing from 7.5 mg to 5 mg while continuing weekly dosing usually produces steadier exposure than taking 7.5 mg every two or three weeks. Planned interval extension is off-label and has less direct evidence than the standard weekly schedule.
When to seek urgent care?
Severe or persistent abdominal pain, repeated vomiting, jaundice, inability to drink, markedly reduced urination, or symptoms of severe hypoglycemia require prompt medical assessment. Do not simply delay the next injection and wait if a serious adverse event is suspected.
References
Related pages
Book an online consultationThis page provides general medical information and does not replace individual diagnosis or treatment. In Japan, Mounjaro is approved for type 2 diabetes; use for weight management is off-label. Dose changes must be decided after medical review.